Trials
Search / Trial NCT05637229

A Serosurvey Study of Hand, Foot, and Mouth Disease in Indonesia

Launched by SINOVAC BIOTECH CO., LTD · Nov 23, 2022

Apply for Trial

Trial Information

Current as of February 05, 2025

Completed

Keywords

ClinConnect Summary

This study is a cross-sectional seroprevalence survey of EV-71, associated with HFMD, among children aged between 6 to 71 months in Bandung, sampled from urban and rural Primary Health Center in Bandung, Indonesia. This study was implemented by Department of Child Health Hasan Sadikin General Hospital/Medical Faculty Universitas Padjadjaran Bandung, West Java. Age-stratified sample of 600 children aged 6-71 months will be conducted from these sites. Samples testing includes routine blood counts, enzyme-linked immunosorbent assays (ELISAs) for enterovirus type 71 (EV71) IgG and ELISAs for ot...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • Children aged 6 months to 71 months.
  • • The participant's parent/guardian receives an explanation and receives a Letter of Consent after the explanation (informed consent) and provided a documented informed consent by parents/legally accepted representative (LAR) participants prior to the study procedures.
  • • Domicile in Bandung and West Bandung District for at least 6 months.
  • Exclusion Criteria:
  • • Children with difficulty to withdraw the blood during blood collection
  • • Children with severe illness who require further treatment

Trial Officials

Rodman Tarigan, Doctor

Principal Investigator

Hasan Sadikin Hospital/School of Medicine, Padjadjaran University, Bandung

About Sinovac Biotech Co., Ltd

Sinovac Biotech Co., Ltd. is a leading biopharmaceutical company headquartered in Beijing, China, specializing in the development, production, and commercialization of vaccines for infectious diseases. With a strong focus on research and innovation, Sinovac is committed to enhancing public health through its vaccine portfolio, which includes vaccines for hepatitis A, hepatitis B, influenza, and COVID-19. The company adheres to stringent international quality standards and regulatory requirements, ensuring the safety and efficacy of its products. Sinovac's dedication to advancing vaccine technology and its global partnerships underscore its role in addressing urgent health challenges worldwide.

Locations

Bandung, , Indonesia

Bandung, , Indonesia

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0

Similar Trials